Name
BIOINF OÜ
Registry code
11359595
Type
OÜ - Limited Liability Company
Status
Registered
Foundation date
08.03.2007 (17)
Financial year
01.01-31.12
Capital
2 556.00 €
Activity
72111 - Research and experimental development on biotechnology
-
-
-
-
-
-
Not submitted
No tax arrears
-
-
| Owner | Representative | Beneficial owner | Roles | |
|---|---|---|---|---|
| Omanikukonto: TOOMAS NEUMAN 22.04.1953 (71) | 100% - 2 556.00 EUR | Board member | Direct ownership | Founder |
| Owner | Representative | Beneficial owner | Roles | |
|---|---|---|---|---|
| dxlabs OÜ 11503052 | 45% - 1 143.00 EUR | - | - | Founder |
| OÜ Cellin Technologies 11543666 | - | - | - | Founder |
| BiotaTec OÜ 11401239 | - | - | - | Founder |
| 2019 27.10.2020 | 2020 28.06.2021 | 2021 09.09.2022 | |
|---|---|---|---|
| Total Revenue | 178 491 € | 14 355 € | 11 000 € |
| Net profit (loss) for the period | 64 382 € | -83 416 € | -22 719 € |
| Profit Margin | 36% | -581% | -207% |
| Current Assets | 166 074 € | 91 982 € | 77 686 € |
| Fixed Assets | 155 586 € | 146 731 € | 154 537 € |
| Total Assets | 321 660 € | 238 713 € | 232 223 € |
| Current Liabilities | 22 653 € | 23 122 € | 39 350 € |
| Non Current Liabilities | - | - | - |
| Total Liabilities | - | - | - |
| Share Capital | - | - | - |
| Equity | 299 007 € | 215 591 € | 192 873 € |
| Employees | 2 | 2 | 2 |
| Turnover | State taxes | Labor taxes and payments | Employees | |
|---|---|---|---|---|
| 2024 Q1 | - | 355.14 € | 211.82 € | - |
| 2023 Q4 | - | 382.76 € | 211.82 € | - |
| 2023 Q3 | - | 680.4 € | 423.64 € | - |
| 2023 Q2 | - | 340.2 € | 211.82 € | - |
| 2023 Q1 | - | 510.3 € | 317.73 € | - |
| 2022 Q4 | - | 510.3 € | 317.73 € | - |
| 2022 Q3 | - | 510.3 € | 317.73 € | - |
| 2022 Q2 | - | 510.3 € | 317.73 € | - |
| 2022 Q1 | 4 200 € | 1 223.68 € | 317.73 € | - |
| 2021 Q4 | - | 2 426.1 € | 2 259.39 € | - |
| 2021 Q3 | - | 3 471.7 € | 3 392.99 € | 1 |
| 2021 Q2 | - | 5 562.9 € | 5 660.19 € | 1 |
| 2021 Q1 | 8 155 € | 5 562.9 € | 5 660.19 € | 2 |
| 2020 Q4 | 6 200 € | 7 131.3 € | 7 360.59 € | 2 |
| 2020 Q3 | - | 6 869.9 € | 7 077.19 € | 3 |
| 2020 Q2 | - | 4 778.7 € | 4 809.99 € | 3 |
| 2020 Q1 | - | 4 773.9 € | 4 829.19 € | 2 |
